The authors describe an HIV-infected patient with moderate renal failure receiving combination antiretroviral therapy. Because of dyslipidaemia he was initially treated with pravastatin but developed rhabdomyolysis after a switch to rosuvastatin. With this case we illustrate that statins as well as antiretroviral therapy are susceptible to clinical relevant drug-drug or drug-disease interactions. Knowledge of these interactions is important to provide patients with the best possible care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3851/IMP1747 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!